EUVIMEDEUVIMED entdecken
Vergleichsstudie

Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure

Yong Hao Yeo iD, Tze Ern Ong iD, Aravinthan Vignarajah, Min Choon Tan iD, Nishanthi Vigneswaramoorthy, Luis Scott, Hicham El-Masry iD, Dan Sorajja, Abhishek Deshmukh iD, Christopher V DeSimone iD, Justin Z Lee

Journal of Cardiovascular Electrophysiology · 2026

DOI: 10.1111/jce.70204 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2026. Verfasst von Yong Hao Yeo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine/Pediatrics, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA. Hauptthemen laut MEDLINE: Heart Failure, Cardiac Resynchronization Therapy, Sarcoidosis, Ventricular Function, Left. Die Arbeit nennt 20 Literaturangaben. Gefördert von: The authors received no specific funding for this study..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cardiac resynchronization therapy (CRT) improves clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, data on its efficacy in patients with sarcoidosis and HFrEF are limited.

Methods

Using the TriNetX network, we identified patients with sarcoidosis, heart failure with a left ventricular ejection fraction (LVEF) below 35%, and either left bundle branch block (LBBB) or prolonged QRS duration ( > 150 ms) between 2014 and 2019. Patients were categorized into two cohorts: (1) those who received CRT and (2) those who received an ICD‐only implant. Five‐year outcomes included all‐cause mortality, all‐cause hospitalization, heart failure exacerbation, and the proportion of patients with improvement in LVEF to greater than 40% and greater than 50%.

Results

Out of 245 eligible patients, we identified a cohort of 87 patients (mean age 62.6 ± 9.5 years) who received CRT and 87 patients (mean age 62.1 ± 11.1 years) who received ICD‐only implant, with similar propensity scores, and included them in a comparative analysis. At 5‐year follow‐up, the CRT group demonstrated outcomes comparable to the ICD‐only implant group for all‐cause mortality (14.9% vs. 20.7%; HR 0.63; 95% CI 0.31–1.28; p = 0.19), all‐cause hospitalization (83.9% vs. 77.0%; HR 1.24; 95% CI 0.89–1.73; p = 0.19), and heart failure exacerbation (28.7% vs. 28.7%; HR 0.90; 95% CI 0.52–1.57; p = 0.72). The proportion of patients with improvement in LVEF to greater than 40% and greater than 50% was also similar in both groups (LVEF > 40%, 43.7% vs. 33.3%; HR 1.30; 95% CI 0.80–2.10; p = 0.29; LVEF > 50%, 31.0% vs. 17.2%; HR 1.72; 95% CI 0.92–3.24; p = 0.09).

Conclusion

CRT implantation had similar long‐term outcomes compared to ICD‐only implantation in patients with sarcoidosis and HFrEF, particularly all‐cause mortality, all‐cause hospitalization, heart failure exacerbation, and the proportion of patients with improvement in LVEF to greater than 40% and greater than 50%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureCardiac Resynchronization TherapySarcoidosisVentricular Function, LeftCardiomyopathiesHumansMaleFemaleMiddle AgedTreatment OutcomeTime FactorsAgedStroke VolumeRisk FactorsRecovery of FunctionPropensity ScoreRisk AssessmentRetrospective StudiesDefibrillators, ImplantableHospitalizationDisease ProgressionAction Potentials

Stichwörter der Autor:innen

cardiac resynchronization therapyheart failureheart failure with reduced ejection fractionmortalitysarcoidosis

Autor:innen und Institutionen

  • Department of Internal Medicine/Pediatrics, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
  • Department of Medicine, One Brooklyn Health System/Interfaith Medical Center, Brooklyn, New York, USA.
  • Department of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, Ohio, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA.
  • Department of Medicine, New York Medical College at St. Michael Medical Center, Newark, New Jersey, USA.
  • Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.

ORCID-Profile: Yong Hao Yeo, Tze Ern Ong, Min Choon Tan, Hicham El-Masry, Abhishek Deshmukh, Christopher V DeSimone

Förderung

  • The authors received no specific funding for this study.

Zitieren

APA

Yeo, Y. H., Ong, T. E., Vignarajah, A., Tan, M. C., Vigneswaramoorthy, N., Scott, L., El-Masry, H., Sorajja, D., Deshmukh, A., DeSimone, C. V., & Lee, J. Z. (2026). Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70204

Vancouver

Yeo YH, Ong TE, Vignarajah A, Tan MC, Vigneswaramoorthy N, Scott L, et al. Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70204

BibTeX
@article{Yeo2026,
  author = {Yeo, Yong Hao and Ong, Tze Ern and Vignarajah, Aravinthan and Tan, Min Choon and Vigneswaramoorthy, Nishanthi and Scott, Luis and El-Masry, Hicham and Sorajja, Dan and Deshmukh, Abhishek and DeSimone, Christopher V and Lee, Justin Z},
  title = {Propensity‐Matched Five‐Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2026},
  doi = {10.1111/jce.70204}
}
Kostenlos starten →